摘要:研究胰腺癌中galpha13介导的炎症和肿瘤抑制的信号机制

IF 12.5 1区 医学 Q1 ONCOLOGY
Khadijeh Karbalaei, Anastasia E. Metropulos, Khulood Alzahrani, Apurba Majumder, Thao N. Pham, Hidayatullah G. Munshi, Mario A. Shields
{"title":"摘要:研究胰腺癌中galpha13介导的炎症和肿瘤抑制的信号机制","authors":"Khadijeh Karbalaei, Anastasia E. Metropulos, Khulood Alzahrani, Apurba Majumder, Thao N. Pham, Hidayatullah G. Munshi, Mario A. Shields","doi":"10.1158/1538-7445.am2025-lb453","DOIUrl":null,"url":null,"abstract":"Host inflammation and tumor-driving genetic alterations significantly influence the immune microenvironment of pancreatic cancer. Indeed, chronic pancreatitis (CP) is a major risk factor for pancreatic ductal adenocarcinoma (PDAC), which is characterized by an early inflammatory response that evolves with tumor initiation and progression. Our previous work highlighted the role of the Pdk1/mTOR signaling axis in promoting pancreatic cancer development, particularly after genetic ablation of Gα13, a heterotrimeric G-protein frequently dysregulated in human tumors. To further investigate how Gα13 modulates the inflammatory response in both pancreatitis and pancreatic cancer, we employed mouse models to examine its role in inflammatory cytokines expression and mTOR signaling. We found that pancreas-specific loss of Gα13 exacerbated tissue injury, elevated pro-inflammatory cytokines, and increased macrophage recruitment in models of pancreatitis. Additionally, loss of Gα13 promoted mTOR signaling in these models, mirroring our earlier findings in pancreatic cancer. Interestingly, while mTOR inhibition alleviated tissue damage and suppressed inflammation in acute pancreatitis, it had no effect in the chronic phase. These findings align with our analysis of human tissue samples, where Gα13 expression was significantly reduced only in acute pancreatitis. Furthermore, in Gα13-deficient tumors, mTOR inhibition suppressed inflammatory cytokine expression and hindered tumor progression. Notably, targeting Pdk1 signaling resulted in a stronger anti-tumor response, with evidence for collagen remodeling and enhanced adaptive immune response. Overall, our findings uncover a novel, targetable pathway regulating both inflammation and tumor progression in pancreatic cancer, which could offer therapeutic opportunities depending on the G-protein status in patients. Citation Format: Khadijeh Karbalaei, Anastasia E. Metropulos, Khulood Alzahrani, Apurba Majumder, Thao N. Pham, Hidayatullah G. Munshi, Mario A. Shields. Elucidating the signaling mechanisms of Galpha13-mediated inflammation and tumor suppression in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB453.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"17 1","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract LB453: Elucidating the signaling mechanisms of Galpha13-mediated inflammation and tumor suppression in pancreatic cancer\",\"authors\":\"Khadijeh Karbalaei, Anastasia E. Metropulos, Khulood Alzahrani, Apurba Majumder, Thao N. Pham, Hidayatullah G. Munshi, Mario A. Shields\",\"doi\":\"10.1158/1538-7445.am2025-lb453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Host inflammation and tumor-driving genetic alterations significantly influence the immune microenvironment of pancreatic cancer. Indeed, chronic pancreatitis (CP) is a major risk factor for pancreatic ductal adenocarcinoma (PDAC), which is characterized by an early inflammatory response that evolves with tumor initiation and progression. Our previous work highlighted the role of the Pdk1/mTOR signaling axis in promoting pancreatic cancer development, particularly after genetic ablation of Gα13, a heterotrimeric G-protein frequently dysregulated in human tumors. To further investigate how Gα13 modulates the inflammatory response in both pancreatitis and pancreatic cancer, we employed mouse models to examine its role in inflammatory cytokines expression and mTOR signaling. We found that pancreas-specific loss of Gα13 exacerbated tissue injury, elevated pro-inflammatory cytokines, and increased macrophage recruitment in models of pancreatitis. Additionally, loss of Gα13 promoted mTOR signaling in these models, mirroring our earlier findings in pancreatic cancer. Interestingly, while mTOR inhibition alleviated tissue damage and suppressed inflammation in acute pancreatitis, it had no effect in the chronic phase. These findings align with our analysis of human tissue samples, where Gα13 expression was significantly reduced only in acute pancreatitis. Furthermore, in Gα13-deficient tumors, mTOR inhibition suppressed inflammatory cytokine expression and hindered tumor progression. Notably, targeting Pdk1 signaling resulted in a stronger anti-tumor response, with evidence for collagen remodeling and enhanced adaptive immune response. Overall, our findings uncover a novel, targetable pathway regulating both inflammation and tumor progression in pancreatic cancer, which could offer therapeutic opportunities depending on the G-protein status in patients. Citation Format: Khadijeh Karbalaei, Anastasia E. Metropulos, Khulood Alzahrani, Apurba Majumder, Thao N. Pham, Hidayatullah G. Munshi, Mario A. Shields. Elucidating the signaling mechanisms of Galpha13-mediated inflammation and tumor suppression in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB453.\",\"PeriodicalId\":9441,\"journal\":{\"name\":\"Cancer research\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":12.5000,\"publicationDate\":\"2025-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.am2025-lb453\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.am2025-lb453","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

宿主炎症和肿瘤驱动基因改变显著影响胰腺癌的免疫微环境。事实上,慢性胰腺炎(CP)是胰腺导管腺癌(PDAC)的主要危险因素,其特征是早期炎症反应随着肿瘤的发生和进展而发展。我们之前的工作强调了Pdk1/mTOR信号轴在促进胰腺癌发展中的作用,特别是在Gα13基因消融后,Gα13是一种在人类肿瘤中经常失调的异三聚体g蛋白。为了进一步研究Gα13如何调节胰腺炎和胰腺癌的炎症反应,我们采用小鼠模型来研究其在炎症细胞因子表达和mTOR信号传导中的作用。我们发现胰腺炎模型中Gα13特异性缺失加重了组织损伤、促炎细胞因子升高和巨噬细胞募集增加。此外,在这些模型中,Gα13的缺失促进了mTOR信号传导,这与我们早期在胰腺癌中的发现相一致。有趣的是,虽然mTOR抑制减轻了急性胰腺炎的组织损伤和抑制炎症,但在慢性期没有作用。这些发现与我们对人体组织样本的分析一致,其中Gα13的表达仅在急性胰腺炎中显着降低。此外,在g α13缺陷肿瘤中,mTOR抑制抑制炎症细胞因子表达,阻碍肿瘤进展。值得注意的是,靶向Pdk1信号导致更强的抗肿瘤反应,有证据表明胶原重塑和适应性免疫反应增强。总之,我们的发现揭示了一种调节胰腺癌炎症和肿瘤进展的新的、可靶向的途径,它可以根据患者的g蛋白状态提供治疗机会。引文格式:Khadijeh Karbalaei, Anastasia E. Metropulos, Khulood Alzahrani, Apurba Majumder, Thao N. Pham, Hidayatullah G. Munshi, Mario A. Shields。胰腺癌中galpha13介导的炎症和肿瘤抑制的信号机制研究[摘要]。摘自:《2025年美国癌症研究协会年会论文集》;第二部分(最新进展,临床试验,并邀请s);2025年4月25日至30日;费城(PA): AACR;中国生物医学工程学报,2015;35(5):444 - 444。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Abstract LB453: Elucidating the signaling mechanisms of Galpha13-mediated inflammation and tumor suppression in pancreatic cancer
Host inflammation and tumor-driving genetic alterations significantly influence the immune microenvironment of pancreatic cancer. Indeed, chronic pancreatitis (CP) is a major risk factor for pancreatic ductal adenocarcinoma (PDAC), which is characterized by an early inflammatory response that evolves with tumor initiation and progression. Our previous work highlighted the role of the Pdk1/mTOR signaling axis in promoting pancreatic cancer development, particularly after genetic ablation of Gα13, a heterotrimeric G-protein frequently dysregulated in human tumors. To further investigate how Gα13 modulates the inflammatory response in both pancreatitis and pancreatic cancer, we employed mouse models to examine its role in inflammatory cytokines expression and mTOR signaling. We found that pancreas-specific loss of Gα13 exacerbated tissue injury, elevated pro-inflammatory cytokines, and increased macrophage recruitment in models of pancreatitis. Additionally, loss of Gα13 promoted mTOR signaling in these models, mirroring our earlier findings in pancreatic cancer. Interestingly, while mTOR inhibition alleviated tissue damage and suppressed inflammation in acute pancreatitis, it had no effect in the chronic phase. These findings align with our analysis of human tissue samples, where Gα13 expression was significantly reduced only in acute pancreatitis. Furthermore, in Gα13-deficient tumors, mTOR inhibition suppressed inflammatory cytokine expression and hindered tumor progression. Notably, targeting Pdk1 signaling resulted in a stronger anti-tumor response, with evidence for collagen remodeling and enhanced adaptive immune response. Overall, our findings uncover a novel, targetable pathway regulating both inflammation and tumor progression in pancreatic cancer, which could offer therapeutic opportunities depending on the G-protein status in patients. Citation Format: Khadijeh Karbalaei, Anastasia E. Metropulos, Khulood Alzahrani, Apurba Majumder, Thao N. Pham, Hidayatullah G. Munshi, Mario A. Shields. Elucidating the signaling mechanisms of Galpha13-mediated inflammation and tumor suppression in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB453.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer research
Cancer research 医学-肿瘤学
CiteScore
16.10
自引率
0.90%
发文量
7677
审稿时长
2.5 months
期刊介绍: Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research. With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445. Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信